Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab (Q33573621)

28 July 2017

title

Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab (English)

1 reference

28 July 2017

1 reference

Lazaro E Aira

1 reference

28 July 2017

Alejandro López-Requena

1 reference

28 July 2017

Dasha Fuentes

1 reference

28 July 2017

Liset Sánchez

1 reference

28 July 2017

Teresita Pérez

1 reference

28 July 2017

Aleida Urquiza

1 reference

28 July 2017

Heber Bautista

1 reference

28 July 2017

Leopoldina Falcón

1 reference

28 July 2017

Patricia Hernández

1 reference

28 July 2017

Zaima Mazorra

1 reference

28 July 2017

publication date

4 March 2014

1 reference

28 July 2017

published in

Monoclonal Antibodies

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

783-793

1 reference

A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Sleep loss and cytokines levels in an experimental model of psoriasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Immunogenicity and autoimmunity during anti-TNF therapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Serum cytokine profile in psoriasis-a case-control study in a tertiary care hospital from northern India

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Comparative efficacy of biologics in psoriasis: a review.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Regulation and functions of the IL-10 family of cytokines in inflammation and disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Cell type-specific regulation of IL-10 expression in inflammation and disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Clinically validated approaches to the treatment of autoimmune diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Multiple sclerosis susceptibility alleles in African Americans.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Psoriasis--pathophysiology, conventional, and alternative approaches to treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Immunopathogenesis and role of T cells in psoriasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Immunopathogenesis of psoriasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Pathogenesis and therapy of psoriasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Etanercept and efalizumab for the treatment of psoriasis: a systematic review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Innate and adaptive immunity and the pathophysiology of psoriasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Psoriasis assessment tools in clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Psoriasis pathophysiology: current concepts of pathogenesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Relevance of CD6-mediated interactions in T cell activation and proliferation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Immunopathogenic mechanisms in psoriasis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

The role of T cells in psoriasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

The immunologic basis for the treatment of psoriasis with new biologic agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort

21 June 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Frontline: Optimal T cell activation requires the engagement of CD6 and CD166.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

CD6: expression during development, apoptosis and selection of human and mouse thymocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Humanization of Predicted T-Cell Epitopes Reduces the Immunogenicity of Chimeric Antibodies: New Evidence Supporting a Simple Method

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Interpretation of cellular proliferation data: Avoid the panglossian

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Elevated rate of Thelper1 (TH1) lymphocytes and serum IFN-γ levels in psoriatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Unique keratinocyte-specific effects of interferon-gamma that protect skin from viruses, identified using transcriptional profiling.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4011922

Cytokine profiles during infliximab monotherapy in psoriatic arthritis

31 October 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.28376

T cells involved in psoriasis vulgaris belong to the Th1 subset

21 January 2018

1 reference

12 December 2020

[Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept]

1 reference

12 December 2020

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis

1 reference

12 December 2020

Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody

1 reference

12 December 2020

Cracking the cytokine code in psoriasis

1 reference

12 December 2020

A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin

1 reference

12 December 2020

TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques

1 reference

12 December 2020

Identification of residues in CD6 which are critical for ligand binding

1 reference

12 December 2020

Evaluation of cytokine serum levels in patients with plaque-type psoriasis

1 reference

12 December 2020

Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

1 reference

12 December 2020

Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia

1 reference

12 December 2020

Immunopathogenesis of psoriasis

1 reference

12 December 2020

[Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis]

1 reference

12 December 2020

Cytokine expression in psoriatic skin lesions during PUVA therapy

1 reference

12 December 2020

Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis

1 reference

12 December 2020

1 reference

12 December 2020

IL-8, IL-12 and IL-10 cytokines generation by neutrophils, fibroblasts and neutrophils- fibroblasts interaction in psoriasis

1 reference

12 December 2020

Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets

1 reference

12 December 2020

Identifiers

DOI

10.4161/MABS.28376

1 reference

28 July 2017

1 reference

28 July 2017

1 reference